Clinical trial Recruiting at 1 site Interventional Ages 13 to 17

Reward Sensitivity Digital App for Adolescent Suicidal Thoughts

Official title: Pilot Development of a Youth-Focused Digital Just-in-Time Adaptive Intervention to Enhance Reward Sensitivity and Reduce Suicidal Ideation

Run by University of Pennsylvania · NCT07661901 · Data updated 2026-11-12

A smartphone app is tested in teens to see if daily check-ins and mood-building activities can reduce suicidal thoughts and improve mood.

Quick facts

Study typeInterventional
Ages13 Years to 17 Years
SexAll
Enrollment20 (estimated)
SponsorUniversity of Pennsylvania
Academic / other
Locations1 site (Philadelphia, Pennsylvania)
StatusRecruiting
StartedAugust 21, 2026
Main results expectedJune 2027
Study endsSeptember 2027
Registry record updatedAugust 26, 2026
Trial IDNCT07661901 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adolescents aged 13-17 with recent suicidal ideation, owning a smartphone, and living in the Philadelphia metropolitan area, plus their English-speaking legal guardians.

Probably not a fit

Teens with high imminent suicide risk or certain psychiatric conditions may not benefit from the digital approach as implemented.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study tests a just-in-time, adaptive digital intervention designed to boost reward sensitivity and positive emotions in adolescents at risk of suicide. The app provides brief, real-time coping activities and mood prompts throughout the day, paired with ecological momentary assessments to track mood, motivation, and context. Phase 1 focuses on co-design with teens and their guardians to ensure usability and acceptability, with ongoing surveys and interviews to evaluate user experience and mood outcomes. Participants are adolescents aged 13-17 with recent suicidal ideation and residing in the Philadelphia area, along with their English-speaking legal guardians. The trial is conducted at the University of Pennsylvania under an interventional framework aimed at suicide prevention through digital health tools.

Why it matters

Potential benefit: If successful, the app could offer a practical way to reduce suicidal thoughts and improve emotional well-being in adolescents who struggle with anhedonia.

How similar studies have gone: Previous digital interventions show promise for mood and suicidality reduction, but this co-design, just-in-time approach is relatively novel in this exact population.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

ADOLESCENTS

* Aged 13-17 years old
* Recent suicidal ideation
* Access to a smartphone device
* Residing in the Philadelphia metropolitan area

LEGALGUARDIANS

* They are the legal guardian of an adolescent that meets all study criteria (see above)
* They can read, write, and speak English

Exclusion Criteria:

ADOLESCENTS

* Psychotic disorder, including schizophrenia, schizoaffective disorder, or psychotic disorder not otherwise specified, with a past year psychotic episode prior to baseline
* Bipolar disorder I diagnosis, with a past year manic episode prior to baseline
* Imminent suicide risk (e.g., active suicidal ideation with a specific plan and intent)

LEGALGUARDIANS

\- There are no exclusion criteria for legal guardians

Where it's running

  • University of Pennsylvania
    Philadelphia, Pennsylvania, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.